A Phase 2/3 interventional study of Lenacapavir Tablet and Lenacapavir Injection in HIV-1-infection, sponsored by Gilead Sciences. Not yet recruiting at 2 sites in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study is to learn more about the study drugs lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) to assess how it is absorbed, modified, distributed and eliminated from the body of young people (the pharmacokinetics (PK) parameters of the drugs). It will also check the safety, and tolerability of LEN in combination with TAB, and ZAB in participants living with human immunodeficiency virus type 1 (HIV-1).
The primary objectives of this study are to evaluate the PK parameters, safety, and tolerability of LEN, TAB, and ZAB.
Gilead Sciences is the lead sponsor of 693 studies on the registry; 27 are open to participants now.
Of its 262 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral LEN 600 mg, subcutaneous (SC) LEN 927 mg, and intravenously (IV) infusions of TAB and ZAB on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. At Week 26: Participants will then receive a second dose of LEN 927 mg SC injection along with TAB and ZAB IV infusion. At Week 52 participants will be given the option to enter the extension phase to continue receiving LEN 600 mg orally and TAB and ZAB IV infusions until participants either discontinue the study treatment or discontinue the extension phase (EXT), or the study is discontinued at the sponsor's sole discretion, whichever occurs first.
Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection · Drug: Teropavimab · Drug: Zinlirvimab
Administered orally
Also known as: LEN
Administered SC
Also known as: LEN, SUNLENCA®
Administered IV
Also known as: TAB, GS-5423
Administered IV
Also known as: ZAB, GS-2872
Pharmacokinetics (PK) parameters: Ctrough for LEN During the First Dosing Cycle (Day 1 to Week 26)
Ctrough is defined as the concentration at the end of the dosing interval. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
Pharmacokinetics (PK) parameters: Ctrough for TAB During the First Dosing Cycle (Day 1 to Week 26)
Ctrough is defined as the concentration at the end of the dosing interval. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
Pharmacokinetics (PK) parameters: Ctrough for ZAB During the First Dosing Cycle (Day 1 to Week 26)
Ctrough is defined as the concentration at the end of the dosing interval. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 26
Time frame: First dose date up to Week 26
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 26
Time frame: First dose date up to Week 26
PK Parameter: Cmax for LEN During the First Dosing Cycle (Day 1 to Week 26)
Cmax is defined as the maximum observed concentration of drug. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: Cmax for TAB During the First Dosing Cycle (Day 1 to Week 26)
Cmax is defined as the maximum observed concentration of drug. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: Cmax for ZAB During the First Dosing Cycle (Day 1 to Week 26)
Cmax is defined as the maximum observed concentration of drug. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: Tmax for LEN During the First Dosing Cycle (Day 1 to Week 26)
Tmax is defined as the time (observed time point) of Cmax. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: Tmax for TAB During the First Dosing Cycle (Day 1 to Week 26)
Tmax is defined as the time (observed time point) of Cmax. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: Tmax for ZAB During the First Dosing Cycle (Day 1 to Week 26)
Tmax is defined as the time (observed time point) of Cmax. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: t1/2 for LEN during the first dosing cycle (Day 1 to Week 26)
t1/2 is defined as the terminal elimination half-life. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: t1/2 for TAB during the first dosing cycle (Day 1 to Week 26)
t1/2 is defined as the terminal elimination half-life. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: t1/2 for ZAB during the first dosing cycle (Day 1 to Week 26)
t1/2 is defined as the terminal elimination half-life. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: AUCtau for LEN During the First Dosing Cycle (Day 1 to Week 26)
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: AUCtau for TAB During the First Dosing Cycle (Day 1 to Week 26)
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: AUCtau for ZAB During the First Dosing Cycle (Day 1 to Week 26)
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Cycle length is 26 weeks.
Time frame: Day 1 to Week 26
PK Parameter: Ctrough for LEN During the Second Dosing Cycle (Week 26 to Week 52)
Ctrough is defined as the observed drug concentration at the end of the dosing interval at steady state. Cycle length is 26 weeks to 52 weeks.
Time frame: Week 26 to Week 52
PK Parameter: Ctrough for TAB During the Second Dosing Cycle (Week 26 to Week 52)
Ctrough is defined as the observed drug concentration at the end of the dosing interval at steady state. Cycle length is 26 weeks to 52 weeks.
Time frame: Week 26 to Week 52
PK Parameter: Ctrough for ZAB During the Second Dosing Cycle (Week 26 to Week 52)
Ctrough is defined as the observed drug concentration at the end of the dosing interval at steady state. Cycle length is 26 weeks to 52 weeks.
Time frame: Week 26 to Week 52
Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52
Time frame: First dose date up to Week 52
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 52
Time frame: First dose date up to Week 52
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 Based on the United States (US) FDA-Defined Snapshot Algorithm
Time frame: Week 26
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 52 Based on the US FDA-Defined Snapshot Algorithm
Time frame: Week 52
Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Weeks 26 Based on the US FDA-Defined Snapshot Algorithm
Time frame: Week 26
Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 52 Based on the US FDA-Defined Snapshot Algorithm
Time frame: Week 52
Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 26
Time frame: Baseline, Week 26
Change From Baseline in CD4 Cell Percentage at Week 26
Time frame: Baseline, Week 26
Change From Baseline in CD4 Cell Count at Week 52
Time frame: Baseline, Week 52
Change From Baseline in CD4 Cell Percentage at Week 52
Time frame: Baseline, Week 52
Percentage of Participants With of Anti-Drug Antibodies (ADA) Against TAB Through Week 26
Time frame: First dose date up to Week 26
Percentage of Participants With Neutralizing Antibodies (NAbs) Against TAB Through Week 26
Time frame: First dose date up to Week 26
Percentage of Participants With ADA Against ZAB through Week 26
Time frame: First dose date up to Week 26
Percentage of Participants With NAbs Against ZAB through Week 26
Time frame: First dose date up to Week 26
Percentage of Participants With ADA Against TAB through Week 52
Time frame: First dose date up to Week 52
Percentage of Participants With NAbs Against TAB through Week 52
Time frame: First dose date up to Week 52
Percentage of Participants With ADA Against ZAB through Week 52
Time frame: First dose date up to Week 52
Percentage of Participants With NAbs Against ZAB through Week 52
Time frame: First dose date up to Week 52
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.